nach oben

Annals of Hematology

Erschienen in:

01.04.2015 | Review Article

Epidemiology of chronic myeloid leukaemia: an update

verfasst von: Martin Höglund, Fredrik Sandin, Bengt Simonsson

Erschienen in: Annals of Hematology | Sonderheft 2/2015

Einloggen, um Zugang zu erhalten

Abstract

National and regional population-based registries are, provided diagnostic accuracy and full coverage of the target population, indispensible tools for epidemiological research. Chronic myeloid leukaemia (CML) registries with more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7–1.0/100,000, a median age at diagnosis of 57–60 years and a male/female ratio of 1.2–1.7. The incidence of CML has been stable over time. Worldwide, variations in the reported incidence of CML may be due to methodological issues, but a true difference between different geographical areas and/or ethnical subgroups cannot be excluded. The prevalence of CML is not well known but has been estimated to be 10–12/100,000 inhabitants with a steady increase due to the dramatic improvement in survival of these patients. In recent population-based studies, CML patients have an overall survival that is comparable to that shown in large clinical trials, though relative survival in patients >70 years is still decreased. The importance of socio-economic factors and health-care setting for outcome and the possible increased risk of secondary cancer in CML are areas of ongoing research.

Socialstyrelsen (2009) Cancer incidence in Sweden. www.socialstyrelsense/publikationer1999/1999-42-8

Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry—history, content, quality and use. Dan Med Bull 44(5):535–539PubMed

Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A, Haematological Malignancy Research N (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 148(5):739–753. doi:10.1111/j.1365-2141.2009.08010.x CrossRefPubMedCentralPubMed

Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, Landgren O (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 121(10):2260–2266. doi:10.1002/ijc.22912 CrossRefPubMed

http://seer.cancer.gov (2014) SEER. Cancer statistics review 1975-2011.

Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L (2011) Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood 118(16):4331–4337. doi:10.1182/blood-2011-01-330332 CrossRefPubMed

Harrison SJ, Johnson PR, Holyoake TL (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J 49(3):87–90PubMed

Höglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevarn B, Myhr-Eriksson K, Ohm L, Olsson-Stromberg U, Sjalander A, Wadenvik H, Simonsson B, Stenke L, Richter J (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122(7):1284–1292. doi:10.1182/blood-2013-04-495598 CrossRefPubMedCentralPubMed

Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, Jack A, Roman E (2014) Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 4(1):e004266. doi:10.1136/bmjopen-2013-004266 CrossRefPubMedCentralPubMed

10.

Lindoerfer D, Pfirrmann M, Saussele S, Hochhaus A, Engel J, Guilhot J, Rosti G, Mayer J, Indrak K, Castagnetti F, Turkina A, Zaritskey A, Steegmann JL, Hellmann A, Thielen N, Cervantes F, Simonsson B, Colita A, Clark RE, Almeida A, Labar B, Marin D, Ossenkoppele GJ, Bogdanovic A, Dyagil I, Porkka K, O’Brien S, Griskevicius L, Panagiotidis P, Thaler J, Zupan I, Lejniece S, Everaus H, Masszi T, Melanthiou F, Hehlmann R, Hasford J, Baccarani M (2013) CML patients in clinical trials represent fairly well the general population of CML patients: a comparative analysis of 5803 patients from the EUTOS Registry, vol 122. vol 21

11.

Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119(17):3890–3899. doi:10.1182/blood-2011-12-379008 CrossRefPubMedCentralPubMed

12.

Berglund A, Holmberg L, Tishelman C, Wagenius G, Eaker S, Lambe M (2010) Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden. Thorax 65(4):327–333. doi:10.1136/thx.2009.125914 CrossRefPubMed

13.

Bjorkholm M, Kristinsson SY, Landgren O, Goldin LR (2013) No familial aggregation in chronic myeloid leukemia. Blood 122(3):460–461. doi:10.1182/blood-2013-05-501312 CrossRefPubMedCentralPubMed

14.

Carlhed R, Bojestig M, Wallentin L, Lindstrom G, Peterson A, Aberg C, Lindahl B (2006) Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J 152(6):1175–1181. doi:10.1016/j.ahj.2006.07.028 CrossRefPubMed

15.

Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R (2009) The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 9:252. doi:10.1186/1471-2407-9-252 CrossRefPubMedCentralPubMed

16.

Chang CS, Lee K, Yang YH, Lin MT, Hsu CN (2011) Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan. Leuk Res 35(5):e53–e54. doi:10.1016/j.leukres.2010.12.034 CrossRefPubMed

17.

Chen Y, Wang H, Kantarjian H, Cortes J (2013) Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 54(7):1411–1417. doi:10.3109/10428194.2012.745525 CrossRefPubMed

18.

Hasford J, Tauscher M, Hochhaus A (2007) Incidence, comorbidity and treatment survey of chronic myeloid leukemia in Germany. ASH Ann Meet Abstr 110(11):2964

19.

Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Muller MC, Hasford J, Heimpel H, Hehlmann R (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23(3):602–604. doi:10.1038/leu.2008.245 CrossRefPubMed

20.

Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22(3):295–302. doi:10.1016/j.beha.2009.07.007 CrossRefPubMed

21.

Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC, Group RW (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48(17):3257–3266. doi:10.1016/j.ejca.2012.05.024 CrossRefPubMed

22.

Gale RP, Cozen W, Goodman MT, Wang FF, Bernstein L (2000) Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 24(8):665–669CrossRefPubMed

23.

Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI (2006) Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev 15(4):367–370CrossRefPubMed

24.

Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34(11):1459–1471. doi:10.1016/j.leukres.2010.03.033 CrossRefPubMed

25.

Hoffmann V, Lindoerfer D, Thaler J, Labar B, Melanthiou F, Mayer J, Everaus H, Porkka K, Guilhot F, Schubert-Fritschle G, Castagnetti F, Lejniece S, Griskevicius L, Thielen N, Hellmann A, Turkina A, Zaritskey A, Bogdanovic A, Indrak K, Zupan I, Casado L-F, Simonsson B, Clark RE, Hehlmann R, Hasford J, Baccarani M (2014) The EUTOS population based registry—incidences of CML across Europe. European Hematology Association Annual Meeting 2014

26.

de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F, International BFMGSGCMLC (2014) Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 167(1):33–47. doi:10.1111/bjh.12977 CrossRefPubMed

27.

Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R (2005) Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 19(6):984–989. doi:10.1038/sj.leu.2403756 CrossRefPubMed

28.

Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, Andersson T, Hoglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18):2514–2520. doi:10.1200/JCO.2011.34.7146 CrossRefPubMedCentralPubMed

29.

Corm S, Micol JB, Leroyer A, Daudignon A, Preudhomme C, Poulain B, Bregman B, Oukessou A, Lai J, Facon T (2008) Kinetic of chronic myeloid leukemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol (Suppl) 26(15S):7088

30.

Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123–3127. doi:10.1002/cncr.26679 CrossRefPubMedCentralPubMed

31.

Ohm L, Lundqvist A, Dickman P, Hoglund M, Persson U, Stenke L, Steen Carlsson K, Bjorkholm M (2014) Real-world cost-effectiveness in chronic myeloid leukaemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma 1–16. doi:10.3109/10428194.2014.953141

32.

Heyssel R, Brill AB, Woodbury LA, Nishimura ET, Ghose T, Hoshino T, Yamasaki M (1960) Leukemia in Hiroshima atomic bomb survivors. Blood 15:313–331PubMed

33.

Musselman JR, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA (2013) Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol 37(4):410–416. doi:10.1016/j.canep.2013.03.012 CrossRefPubMed

34.

Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D’Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553–561. doi:10.1093/jnci/djr060 CrossRefPubMed

35.

Pulte D, Gondos A, Redaniel MT, Brenner H (2011) Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist 16(5):663–671. doi:10.1634/theoncologist. 2010-0393 CrossRefPubMedCentralPubMed

36.

Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT (2013) Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer 119(14):2620–2629. doi:10.1002/cncr.28106 CrossRefPubMed

37.

Shah BK, Ghimire KB (2013) Chronic myeloid leukemia survival in older population in the United States. Leuk Lymphoma. doi:10.3109/10428194.2013.775435 PubMedCentral

38.

Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, Hromas RA (2010) Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 123(8):764 e761-769. doi:10.1016/j.amjmed.2010.03.018

39.

Proetel U, Pletsch N, Lauseker M, Muller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Muller L, Hanel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saussele S, German Chronic Myeloid Leukemia Study G, Schweizerische Arbeitsgemeinschaft fur Klinische K (2014) Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol 93(7):1167–1176. doi:10.1007/s00277-014-2041-0 CrossRefPubMedCentralPubMed

40.

Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591–5599. doi:10.1182/blood-2010-12-324228 CrossRefPubMed

41.

Breccia M, Alimena G (2013) The role of comorbidities in chronic myeloid leukemia. Leuk Res 37(7):729–730. doi:10.1016/j.leukres.2013.04.001 CrossRefPubMed

42.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373–383CrossRefPubMed

43.

Krauss MP, Lauseker M, Hehlmann R, Proetel U, Schreiber A, Kalmanti L, Hanfstein B, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Baerlocher GM, Heim D, Krause SW, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC (2013) Comorbidity, measured by the Charlson index, has no negative impact on remission in patients with chronic myeloid leukemia: results of the randomized CML-Study IV, vol 122. vol 21.

44.

Faber E, Muzik J, Koza V, Demeckova E, Voglova J, Demitrovicova L, Chudej J, Markuljak I, Cmunt E, Kozak T, Tothova E, Jarosova M, Dusek L, Indrak K (2011) Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000—a report from the population-based CAMELIA Registry. Eur J Haematol 87(2):157–168. doi:10.1111/j.1600-0609.2011.01637.x CrossRefPubMed

45.

Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CMLSG (2014) The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 123(16):2494–2496. doi:10.1182/blood-2013-11-539742 CrossRefPubMed

46.

Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118(25):6515–6520. doi:10.1182/blood-2011-04-348755 CrossRefPubMed

47.

Gunnarsson N, Stenke L, Höglund M, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Richer J, Wadenvik H, Wallvik J, Själander A (2014) Second malignancies following treatment of chronic myeloid leukemia in the tyrosine kinase inhibitor era. ASH Annual Meeting Abstracts 2014, abstract no 154. Br. J. Haematol. doi:10.1111/bjh.13346

48.

Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG (2010) Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 172(9):1028–1033. doi:10.1093/aje/kwq262 CrossRefPubMed

49.

Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K, Michalovicova Z, Demitrovicova L, Cmunt E, Novakova L, Tothova E, Belohlavkova P, Mayer J, Indrak K (2011) Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 58(3):256–262CrossRefPubMed

50.

Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O’Brien S, Cortes J (2011) Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353–4358. doi:10.1182/blood-2011-06-362889 CrossRefPubMedCentralPubMed

Titel: Epidemiology of chronic myeloid leukaemia: an update
verfasst von: Martin Höglund
Fredrik Sandin
Bengt Simonsson
Publikationsdatum: 01.04.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe Sonderheft 2/2015
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-015-2314-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2015

Managing pregnancy in chronic myeloid leukaemia

Management of chronic myeloid leukemia in blast crisis

The interferon-alpha revival in CML

Response-related predictors of survival in CML

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death